Overview
Crystalys Therapeutics is a biopharmaceutical company developing dotinurad for gout, with the program moving through global Phase 3 development and preparation for commercialization. Its target market is gout treatment, where the company is focused on bringing the therapy to patients and prescribing clinicians internationally. The company announced a $130 million Series B financing on July 22, 2026, bringing disclosed funding to $130 million across one round. The round is intended to advance late-stage clinical development and commercialization activities; no AI platform or AI-enabled technology was described in the provided funding context.
Funding History
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
Frequently Asked Questions
- How much has Crystalys Therapeutics raised in total?
- Crystalys Therapeutics has raised a total of $130M across 1 funding round.
- What does Crystalys Therapeutics do?
- Crystalys Therapeutics is a biopharmaceutical company developing dotinurad for gout, with the program moving through global Phase 3 development and preparation for commercialization. Its target market is gout treatment, where the company is focused on bringing the therapy to patients and prescribing clinicians internationally. The company announced a $130 million Series B financing on July 22, 2026, bringing disclosed funding to $130 million across one round. The round is intended to advance late-stage clinical development and commercialization activities; no AI platform or AI-enabled technology was described in the provided funding context.
- Where is Crystalys Therapeutics headquartered?
- Crystalys Therapeutics is headquartered in San Francisco, CA.
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.